Zinc Supplementation and the Prevention and Treatment of Sepsis in Young Infants: A Systematic Review and Meta-Analysis

Omar Irfan; Robert E Black; Zohra S Lassi; Zulfiqar A Bhutta

doi:10.1159/000521275

Zinc Supplementation and the Prevention and Treatment of Sepsis in Young Infants: A Systematic Review and Meta-Analysis

Neonatology. 2022;119(2):164-175. doi: 10.1159/000521275.

Authors

Omar Irfan¹, Robert E Black², Zohra S Lassi³, Zulfiqar A Bhutta^{1

4}

Affiliations

¹ Centre for Global Child Health, The Hospital for Sick Children, Toronto, Ontario, Canada.
² Department Global Disease Epidemiology and Control, Baltimore, Maryland, USA.
³ Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia.
⁴ Institute for Global Health & Development, The Aga Khan University, Karachi, Pakistan.

PMID: 38606924
DOI: 10.1159/000521275

Abstract

Background: Prematurity and low birth weight are major risk factors for neonatal sepsis. Zinc supplements have been previously shown to be beneficial in pregnancy and small for gestational age birth outcomes. There is sparse information, however, on the potential benefits of zinc supplementation to prevent or treat serious infections in this age group.

Objective: The aim of this study was to assess the efficacy of preventive and therapeutic zinc supplementation in young infant (<4 months) sepsis.

Methods: MEDLINE, Cochrane CENTRAL, and other databases were searched from inception until 18 June 2021. Studies assessing preventive and therapeutic zinc supplementation in young infants in relation to incidence and outcomes of suspected sepsis were included. Meta-analyses of pooled effects were calculated for sepsis-related outcomes.

Results: Nine randomized controlled trials involving 2,553 infants were included. Six studies reported therapeutic efficacy, whereas 3 evaluated preventive benefits of zinc supplementation. Preventive studies suggest a protective effect of zinc supplementation on neonatal mortality rate (NMR) (risk ratio (RR) 0.28; 95% CI 0.12-0.67, LOW certainty), but with no effect on the incidence of sepsis, both in preterm neonates. Among young infants, therapeutic zinc was associated with significant reductions in treatment failure (RR 0.61; 95% CI 0.44-0.85; MODERATE certainty) and further subgroup analysis showing significant reduction in infant mortality rate with 3 mg/kg/twice a day dosage only (RR 0.49; 95% CI 0.27-0.87, LOW certainty). Therapeutic zinc supplementation in neonates did not show any effect on hospital stay or NMR.

Conclusion: Zinc supplementation could potentially reduce mortality and treatment failure in young infants but has no noteworthy influence on hospital stay and in the prevention of sepsis. Further studies with larger sample sizes are needed to confirm the direction and magnitude of effects if any.

Keywords: Efficacy; Mortality; Neonatal sepsis; Treatment; Young infant sepsis; Zinc.

Publication types

Meta-Analysis